Spero Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
SPRO$1.07+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except unit, share and per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $52,889 | $76,333 |
| Collaboration receivable, current - related party | 49,391 | 49,152 |
| Other receivables | 3,085 | 1,545 |
| Prepaid expenses and other current assets | 1,911 | 4,178 |
| Total current assets | 107,276 | 131,208 |
| Property and equipment, net | — | 2 |
| Operating lease right-of-use assets | 3,114 | 4,155 |
| Collaboration receivable, non-current - related party | — | 46,590 |
| Other assets | 153 | 435 |
| Total assets | $110,543 | $182,390 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $7,306 | $1,378 |
| Accrued expenses and other current liabilities | 17,724 | 6,557 |
| Operating lease liabilities | 1,746 | 1,718 |
| Income taxes payable | 174 | 387 |
| Deferred revenue, current | 368 | 2,132 |
| Deferred revenue, current - related party | 21,756 | 24,981 |
| Total current liabilities | 49,074 | 37,153 |
| Non-current operating lease liabilities | 2,551 | 3,825 |
| Deferred revenue, non-current | 12,219 | 10,825 |
| Deferred revenue, non-current - related party | 576 | 23,606 |
| Other long-term liabilities | — | 87 |
| Total liabilities | 64,420 | 75,496 |
| Commitments and contingencies (Note 11) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2024 and 2023; 54,593,527 shares issued and outstanding as of December 31, 2024 and 52,999,680 shares issued and outstanding as of December 31, 2023 | 55 | 53 |
| Additional paid-in capital | 505,706 | 497,913 |
| Accumulated deficit | (459,638) | (391,072) |
| Total stockholders' equity | 46,123 | 106,894 |
| Total liabilities and stockholders' equity | $110,543 | $182,390 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.